| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dronabinol | 15 | 2014 | 31 | 2.650 |
Why?
|
| Cannabinoids | 9 | 2016 | 41 | 1.910 |
Why?
|
| Anti-Inflammatory Agents | 9 | 2016 | 165 | 1.480 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 9 | 2016 | 202 | 1.350 |
Why?
|
| gamma-Linolenic Acid | 14 | 2002 | 16 | 1.080 |
Why?
|
| Arthritis, Rheumatoid | 20 | 2008 | 346 | 0.990 |
Why?
|
| Inflammation | 12 | 2016 | 1191 | 0.990 |
Why?
|
| Interleukin-1 | 9 | 2003 | 155 | 0.950 |
Why?
|
| Monocytes | 10 | 2008 | 362 | 0.910 |
Why?
|
| Endocannabinoids | 4 | 2016 | 22 | 0.860 |
Why?
|
| Synovial Membrane | 6 | 2008 | 21 | 0.780 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2008 | 247 | 0.600 |
Why?
|
| Eicosanoids | 8 | 2009 | 25 | 0.580 |
Why?
|
| Synovial Fluid | 8 | 2008 | 29 | 0.570 |
Why?
|
| T-Lymphocytes | 9 | 2003 | 1007 | 0.540 |
Why?
|
| Fatty Acids | 9 | 2007 | 197 | 0.520 |
Why?
|
| Arachidonic Acids | 5 | 2009 | 27 | 0.510 |
Why?
|
| Prostaglandins | 7 | 2008 | 18 | 0.490 |
Why?
|
| Fibrosis | 1 | 2016 | 172 | 0.470 |
Why?
|
| Analgesics | 3 | 2007 | 102 | 0.420 |
Why?
|
| Plant Oils | 6 | 2009 | 63 | 0.410 |
Why?
|
| Cells, Cultured | 17 | 2008 | 2190 | 0.400 |
Why?
|
| Lymphocyte Activation | 7 | 2008 | 752 | 0.390 |
Why?
|
| PPAR gamma | 3 | 2007 | 77 | 0.370 |
Why?
|
| Fatty Acids, Unsaturated | 4 | 1999 | 28 | 0.370 |
Why?
|
| Antirheumatic Agents | 3 | 2007 | 227 | 0.360 |
Why?
|
| Pain | 2 | 2004 | 398 | 0.360 |
Why?
|
| Cannabinoid Receptor Modulators | 2 | 2009 | 8 | 0.340 |
Why?
|
| Cannabis | 4 | 2009 | 54 | 0.330 |
Why?
|
| Glycine | 3 | 2009 | 49 | 0.320 |
Why?
|
| Apoptosis | 2 | 2008 | 1095 | 0.320 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2007 | 607 | 0.310 |
Why?
|
| Rheumatic Diseases | 2 | 2002 | 42 | 0.310 |
Why?
|
| Fibroblasts | 3 | 2009 | 415 | 0.310 |
Why?
|
| Macrophages | 5 | 2008 | 1050 | 0.300 |
Why?
|
| Arachidonic Acid | 6 | 2008 | 38 | 0.300 |
Why?
|
| Lipoxins | 1 | 2009 | 7 | 0.290 |
Why?
|
| Arthritis, Experimental | 5 | 2007 | 30 | 0.290 |
Why?
|
| Psychotropic Drugs | 3 | 2008 | 81 | 0.280 |
Why?
|
| Osteoclasts | 1 | 2008 | 53 | 0.270 |
Why?
|
| Arthritis | 3 | 2005 | 52 | 0.270 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2007 | 7 | 0.260 |
Why?
|
| Linolenic Acids | 4 | 1991 | 6 | 0.250 |
Why?
|
| Humans | 49 | 2016 | 64914 | 0.250 |
Why?
|
| Animals | 22 | 2016 | 21347 | 0.240 |
Why?
|
| Eicosapentaenoic Acid | 3 | 1997 | 18 | 0.230 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 6 | 1999 | 22 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2014 | 853 | 0.230 |
Why?
|
| Cannabidiol | 1 | 2004 | 3 | 0.220 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2004 | 9 | 0.220 |
Why?
|
| Cell Differentiation | 2 | 2008 | 1385 | 0.220 |
Why?
|
| Rats | 11 | 2009 | 1995 | 0.220 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 1997 | 20 | 0.210 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2003 | 29 | 0.200 |
Why?
|
| Cyclooxygenase 2 | 4 | 2008 | 61 | 0.200 |
Why?
|
| Eicosanoic Acids | 2 | 1994 | 3 | 0.190 |
Why?
|
| RNA, Messenger | 6 | 2008 | 1578 | 0.190 |
Why?
|
| Knee Joint | 1 | 2005 | 310 | 0.180 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 20 | 0.180 |
Why?
|
| Mice | 11 | 2014 | 11120 | 0.180 |
Why?
|
| Liver Diseases | 1 | 2002 | 158 | 0.170 |
Why?
|
| Adjuvants, Immunologic | 4 | 2000 | 235 | 0.170 |
Why?
|
| Prostaglandins E | 4 | 1991 | 8 | 0.150 |
Why?
|
| Receptor, Cannabinoid, CB2 | 2 | 2014 | 10 | 0.150 |
Why?
|
| Interleukin-8 | 3 | 2005 | 96 | 0.150 |
Why?
|
| Dinoprostone | 3 | 1994 | 41 | 0.150 |
Why?
|
| In Vitro Techniques | 4 | 2003 | 493 | 0.140 |
Why?
|
| Cell Division | 3 | 2003 | 448 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2009 | 95 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1999 | 279 | 0.130 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 3 | 2005 | 20 | 0.130 |
Why?
|
| Fish Oils | 2 | 1995 | 43 | 0.130 |
Why?
|
| Interleukin-2 | 3 | 1994 | 166 | 0.130 |
Why?
|
| Administration, Oral | 4 | 2002 | 371 | 0.130 |
Why?
|
| Disease Models, Animal | 5 | 2009 | 2284 | 0.120 |
Why?
|
| Phospholipases | 2 | 1986 | 9 | 0.120 |
Why?
|
| Phospholipases A | 2 | 1986 | 15 | 0.120 |
Why?
|
| Type C Phospholipases | 2 | 1986 | 34 | 0.120 |
Why?
|
| Arthritis, Psoriatic | 2 | 2008 | 32 | 0.110 |
Why?
|
| Protein Kinase C | 1 | 1995 | 102 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2008 | 1035 | 0.110 |
Why?
|
| Interleukin-6 | 2 | 2007 | 325 | 0.110 |
Why?
|
| Immune System | 1 | 1995 | 132 | 0.110 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2014 | 15 | 0.110 |
Why?
|
| Neutrophils | 2 | 2009 | 396 | 0.100 |
Why?
|
| Liposomes | 1 | 1994 | 116 | 0.100 |
Why?
|
| Gene Expression | 4 | 2005 | 856 | 0.100 |
Why?
|
| Immunity, Cellular | 2 | 1993 | 172 | 0.100 |
Why?
|
| Receptors, Cannabinoid | 3 | 2009 | 7 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1994 | 241 | 0.100 |
Why?
|
| Male | 14 | 2009 | 30904 | 0.100 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2004 | 151 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 1997 | 384 | 0.090 |
Why?
|
| Molecular Structure | 2 | 2003 | 316 | 0.090 |
Why?
|
| Cell Survival | 3 | 1999 | 582 | 0.090 |
Why?
|
| Polyunsaturated Alkamides | 2 | 2002 | 6 | 0.090 |
Why?
|
| Membrane Proteins | 3 | 2005 | 922 | 0.080 |
Why?
|
| Chemotactic Factors | 1 | 1991 | 26 | 0.080 |
Why?
|
| Antibody Formation | 1 | 1991 | 110 | 0.080 |
Why?
|
| Structure-Activity Relationship | 2 | 2014 | 356 | 0.080 |
Why?
|
| Synovitis | 4 | 1999 | 30 | 0.080 |
Why?
|
| Acute-Phase Reaction | 1 | 1989 | 18 | 0.080 |
Why?
|
| Fibromyalgia | 1 | 2009 | 15 | 0.070 |
Why?
|
| Female | 12 | 2014 | 33873 | 0.070 |
Why?
|
| Isoenzymes | 2 | 2000 | 129 | 0.070 |
Why?
|
| Peritonitis | 1 | 2009 | 43 | 0.070 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 24 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2008 | 870 | 0.070 |
Why?
|
| RANK Ligand | 1 | 2008 | 23 | 0.070 |
Why?
|
| Anilides | 1 | 2007 | 18 | 0.070 |
Why?
|
| Cell Separation | 3 | 2008 | 147 | 0.070 |
Why?
|
| Middle Aged | 8 | 2008 | 18170 | 0.070 |
Why?
|
| Prostaglandin Antagonists | 1 | 2007 | 2 | 0.070 |
Why?
|
| Phorbol Esters | 1 | 2007 | 4 | 0.070 |
Why?
|
| Drug Design | 2 | 2007 | 137 | 0.060 |
Why?
|
| Chromatography, Thin Layer | 1 | 2007 | 16 | 0.060 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2007 | 42 | 0.060 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 53 | 0.060 |
Why?
|
| Edema | 1 | 2007 | 42 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 17 | 0.060 |
Why?
|
| Alanine | 1 | 2007 | 50 | 0.060 |
Why?
|
| Interleukin-1alpha | 1 | 2007 | 25 | 0.060 |
Why?
|
| Blood Platelets | 3 | 1996 | 108 | 0.060 |
Why?
|
| Cartilage | 1 | 2007 | 35 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 195 | 0.060 |
Why?
|
| Liver | 2 | 2002 | 868 | 0.060 |
Why?
|
| Sulfhydryl Compounds | 1 | 2007 | 52 | 0.060 |
Why?
|
| Lipopolysaccharides | 2 | 2001 | 621 | 0.060 |
Why?
|
| Leukocytes | 1 | 2007 | 105 | 0.060 |
Why?
|
| Aspirin | 1 | 1987 | 171 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2008 | 219 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2007 | 277 | 0.060 |
Why?
|
| Embryo, Mammalian | 1 | 2007 | 158 | 0.060 |
Why?
|
| Signal Transduction | 4 | 1999 | 3154 | 0.060 |
Why?
|
| Chronic Disease | 4 | 2007 | 741 | 0.060 |
Why?
|
| Stem Cells | 1 | 2008 | 275 | 0.060 |
Why?
|
| Adult | 8 | 2008 | 17279 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2004 | 1551 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 108 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2004 | 15 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 800 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2007 | 507 | 0.050 |
Why?
|
| Cytokines | 3 | 2008 | 959 | 0.050 |
Why?
|
| Joints | 1 | 2003 | 33 | 0.050 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2003 | 20 | 0.050 |
Why?
|
| Annexin A5 | 1 | 2003 | 20 | 0.050 |
Why?
|
| DNA Fragmentation | 1 | 2003 | 34 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2005 | 212 | 0.050 |
Why?
|
| CD3 Complex | 2 | 2008 | 64 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2005 | 666 | 0.050 |
Why?
|
| Cyclic AMP | 2 | 1989 | 144 | 0.050 |
Why?
|
| Behavior | 1 | 2003 | 36 | 0.050 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2002 | 1 | 0.050 |
Why?
|
| Felty Syndrome | 1 | 2002 | 2 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2003 | 108 | 0.050 |
Why?
|
| Hemochromatosis | 1 | 2002 | 7 | 0.050 |
Why?
|
| Scleroderma, Systemic | 1 | 2002 | 20 | 0.050 |
Why?
|
| Cell Line | 1 | 2007 | 2036 | 0.050 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2002 | 24 | 0.050 |
Why?
|
| Lymphocytes | 2 | 1995 | 204 | 0.050 |
Why?
|
| RNA Stability | 1 | 2003 | 104 | 0.050 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2002 | 13 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 1995 | 460 | 0.050 |
Why?
|
| Caspases | 1 | 2003 | 176 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 1994 | 740 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2002 | 29 | 0.050 |
Why?
|
| Sjogren's Syndrome | 1 | 2002 | 25 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 403 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2007 | 2154 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2001 | 50 | 0.040 |
Why?
|
| Phagocytes | 2 | 1995 | 52 | 0.040 |
Why?
|
| Immunity | 1 | 1982 | 108 | 0.040 |
Why?
|
| Lipids | 2 | 1996 | 327 | 0.040 |
Why?
|
| Fatty Acids, Essential | 2 | 1993 | 8 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 426 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2001 | 85 | 0.040 |
Why?
|
| Biopsy | 1 | 2002 | 454 | 0.040 |
Why?
|
| Phenotype | 1 | 2005 | 1232 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2001 | 116 | 0.040 |
Why?
|
| Membrane Lipids | 2 | 1993 | 25 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1982 | 180 | 0.040 |
Why?
|
| Hydrolysis | 1 | 2000 | 147 | 0.040 |
Why?
|
| Osteoarthritis, Knee | 1 | 2005 | 396 | 0.040 |
Why?
|
| Aged | 5 | 2008 | 14884 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2000 | 324 | 0.040 |
Why?
|
| Uric Acid | 2 | 1989 | 48 | 0.040 |
Why?
|
| Linoleic Acids | 2 | 1988 | 9 | 0.040 |
Why?
|
| Cyclooxygenase 1 | 1 | 1998 | 6 | 0.030 |
Why?
|
| Injections, Intradermal | 1 | 1998 | 12 | 0.030 |
Why?
|
| Freund's Adjuvant | 1 | 1998 | 14 | 0.030 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1997 | 4 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 1999 | 181 | 0.030 |
Why?
|
| Palmitic Acid | 1 | 1997 | 14 | 0.030 |
Why?
|
| Rats, Inbred Lew | 1 | 1998 | 106 | 0.030 |
Why?
|
| Safflower Oil | 1 | 1997 | 1 | 0.030 |
Why?
|
| Sunflower Oil | 1 | 1997 | 5 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 1998 | 69 | 0.030 |
Why?
|
| Flax | 1 | 1997 | 7 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 1998 | 111 | 0.030 |
Why?
|
| Helianthus | 1 | 1997 | 6 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2007 | 344 | 0.030 |
Why?
|
| Binding Sites | 2 | 2014 | 920 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 1999 | 380 | 0.030 |
Why?
|
| Placebos | 1 | 1996 | 73 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2001 | 642 | 0.030 |
Why?
|
| Phospholipases A2 | 2 | 1986 | 15 | 0.030 |
Why?
|
| Kinetics | 1 | 1997 | 759 | 0.030 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 1995 | 7 | 0.030 |
Why?
|
| Acute Disease | 2 | 1994 | 664 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 1995 | 74 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1995 | 15 | 0.030 |
Why?
|
| Docosahexaenoic Acids | 1 | 1995 | 31 | 0.030 |
Why?
|
| Skin | 1 | 1998 | 415 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2014 | 17 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2001 | 1634 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2014 | 114 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1995 | 177 | 0.030 |
Why?
|
| Mice, Inbred NZB | 2 | 1983 | 21 | 0.020 |
Why?
|
| Alprostadil | 1 | 1993 | 6 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 622 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 1993 | 414 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2014 | 340 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2007 | 5583 | 0.020 |
Why?
|
| Time Factors | 2 | 1997 | 3755 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2014 | 236 | 0.020 |
Why?
|
| Dietary Fats | 1 | 1993 | 178 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1992 | 112 | 0.020 |
Why?
|
| Phagocytosis | 2 | 1988 | 268 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 1991 | 61 | 0.020 |
Why?
|
| SRS-A | 1 | 1990 | 2 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1991 | 152 | 0.020 |
Why?
|
| Leukotriene B4 | 1 | 1990 | 12 | 0.020 |
Why?
|
| Blood Cells | 1 | 1990 | 17 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1990 | 71 | 0.020 |
Why?
|
| Pregnancy | 1 | 1997 | 2366 | 0.020 |
Why?
|
| Indomethacin | 1 | 1989 | 23 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 1994 | 1557 | 0.020 |
Why?
|
| Oenothera biennis | 1 | 1988 | 1 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1988 | 149 | 0.020 |
Why?
|
| Tumor Necrosis Factors | 1 | 2008 | 8 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1991 | 711 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2008 | 37 | 0.020 |
Why?
|
| CD28 Antigens | 1 | 2008 | 61 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2008 | 194 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2008 | 131 | 0.020 |
Why?
|
| Linoleic Acid | 1 | 1987 | 19 | 0.020 |
Why?
|
| Phospholipids | 1 | 1987 | 81 | 0.020 |
Why?
|
| Prospective Studies | 1 | 1994 | 3303 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2007 | 110 | 0.020 |
Why?
|
| Telomere | 1 | 2007 | 58 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2007 | 135 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2007 | 419 | 0.010 |
Why?
|
| Ligands | 1 | 2007 | 416 | 0.010 |
Why?
|
| Adolescent | 1 | 1996 | 6283 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 1985 | 39 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2007 | 677 | 0.010 |
Why?
|
| Diet | 1 | 1989 | 533 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2007 | 790 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 1579 | 0.010 |
Why?
|
| Arthus Reaction | 1 | 1983 | 1 | 0.010 |
Why?
|
| Dermatitis, Contact | 1 | 1983 | 12 | 0.010 |
Why?
|
| Chemistry | 1 | 1983 | 31 | 0.010 |
Why?
|
| Granuloma | 1 | 1983 | 43 | 0.010 |
Why?
|
| Crystallization | 1 | 1983 | 98 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 1983 | 96 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2007 | 1134 | 0.010 |
Why?
|
| Exudates and Transudates | 2 | 1973 | 12 | 0.010 |
Why?
|
| Bone Resorption | 1 | 1983 | 46 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 1994 | 5776 | 0.010 |
Why?
|
| Sheep | 1 | 1983 | 189 | 0.010 |
Why?
|
| Rabbits | 1 | 1983 | 338 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2007 | 1159 | 0.010 |
Why?
|
| Cattle | 1 | 1983 | 318 | 0.010 |
Why?
|
| Capillary Permeability | 1 | 1982 | 16 | 0.010 |
Why?
|
| Nephritis | 1 | 1982 | 11 | 0.010 |
Why?
|
| Protein Binding | 1 | 2007 | 1642 | 0.010 |
Why?
|
| Dogs | 1 | 1983 | 316 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 1982 | 40 | 0.010 |
Why?
|
| Receptors, Drug | 1 | 2001 | 4 | 0.010 |
Why?
|
| Diglycerides | 1 | 2001 | 24 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2001 | 44 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2001 | 168 | 0.010 |
Why?
|
| Base Sequence | 2 | 1995 | 1329 | 0.010 |
Why?
|
| Biomarkers | 1 | 2007 | 1473 | 0.010 |
Why?
|
| Glioma | 1 | 2001 | 99 | 0.010 |
Why?
|
| Adipocytes | 1 | 2003 | 273 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1995 | 1985 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2001 | 603 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 687 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2001 | 396 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1982 | 564 | 0.010 |
Why?
|
| Thapsigargin | 1 | 1997 | 17 | 0.010 |
Why?
|
| Inositol Phosphates | 1 | 1997 | 17 | 0.010 |
Why?
|
| DNA | 1 | 1982 | 852 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 1995 | 13 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1995 | 30 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1997 | 367 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1995 | 48 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1995 | 300 | 0.010 |
Why?
|
| Calcium | 1 | 1997 | 583 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1973 | 18 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1973 | 33 | 0.010 |
Why?
|
| Glucuronidase | 1 | 1973 | 25 | 0.010 |
Why?
|
| Adrenalectomy | 1 | 1973 | 24 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 1973 | 51 | 0.010 |
Why?
|
| Adrenal Glands | 1 | 1973 | 34 | 0.010 |
Why?
|
| Tarsal Joints | 1 | 1973 | 4 | 0.010 |
Why?
|
| Glycosaminoglycans | 1 | 1973 | 20 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1997 | 877 | 0.010 |
Why?
|
| Tibia | 1 | 1973 | 75 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1973 | 128 | 0.010 |
Why?
|
| Cartilage, Articular | 1 | 1973 | 79 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 1594 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 244 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 513 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1995 | 907 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1973 | 418 | 0.000 |
Why?
|